Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Vinson WaldenCity Different Investments - Global Equity | Life Sciences Tools & ServicesLife Sciences Tools & Services | City Different Investments Global Equity - ICLR ICON Plc (ICLR) was a new purchase and became the top contributor to our results for the second quarter. Founded in 1990... | BULL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Tony ConiarisHarris Associates Concentrated Strategy | Life Sciences Tools & ServicesLife Sciences Tools & Services | Harris Associates Concentrated Strategy - ICLR ICON was a contributor during the quarter. The Ireland-headquartered and... | BULL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Michael P. McCloskeyGreensKeeper Value Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | GreensKeeper Value Fund - ICLR Our top performer in the second quarter was ICON plc (ICLR), which gained 57%. The surge followed... | NEUTRAL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Michael P. McCloskeyGreensKeeper Value Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long ICLR (ICON Plc) ICON Plc fell sharply after announcing an internal investigation into revenue recognition, which the manager views as a temporary overreaction since the restatement impact is expected to be under 2%. The manager added... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | LVS Advisory LLCLVS Advisory - Growth | Life Sciences Tools & ServicesLife Sciences Tools & Services | Short ICLR (Icon Plc) LVS Advisory divested from Icon Plc after deeper research revealed that its aggressive M&A strategy created project disruptions, high employee turnover, and substantial debt. Concluding that Medpace's... | BEAR | View Pitch → | |
| Aug 21, 2026 | Fund Letter | LVS Advisory LLCLVS Advisory - Event Driven | Life Sciences Tools & ServicesLife Sciences Tools & Services | Short ICLR (Icon Plc) LVS purchased Icon Plc expecting strong CRO sector tailwinds and an attractive valuation, but deeper fundamental research revealed critical flaws. The firm's heavy... | BEAR | View Pitch → | |
| Jan 27, 2026 | Fund Letter | Michael P. McCloskeyGreensKeeper Value Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | GreensKeeper Value Fund 2025 Q4 (ICLR) Since publishing our thesis on ICON PLC, the industry backdrop has improved. Large pharmaceutical companies... | BULL | View Pitch → | |
| Jan 27, 2026 | Fund Letter | Graeme Forster, Bo SangOrbis International Equity | Life Sciences Tools & ServicesLife Sciences Tools & Services | Orbis International Equity 2025 Q4 (ICLR) Similarly, Icon, a top holding that performs drug trials for the pharma and biotech ecosystem, has been tarred with the same brush as the rest of the sector. The shares halved,... | BULL | View Pitch → | |
| Dec 4, 2025 | Fund Letter | Anthony PhilippDiamond Hill Mid Cap | Life Sciences Tools & ServicesLife Sciences Tools & Services | Diamond Hill Mid Cap 2025 Q2 (ICLR) Among our bottom Q2 individual contributors were ICON and Post Holdings. ICON's shares declined... | BEAR | View Pitch → | |
| Dec 4, 2025 | Fund Letter | Dmitry Khaykin, Deepon NagClearBridge Investments Large Cap Value | Life Sciences Tools & ServicesLife Sciences Tools & Services | ClearBridge Investments Large Cap Value 2025 Q2 (ICLR) Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed... | BULL | View Pitch → | |
| Dec 4, 2025 | Fund Letter | Erica Furfaro, Margaret VitranoClearBridge Investments Large Cap Growth Strategy | Life Sciences Tools & ServicesLife Sciences Tools & Services | ClearBridge Investments Large Cap Growth Strategy 2025 Q2 (ICLR) Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed... | BULL | View Pitch → | |
| Dec 4, 2025 | Fund Letter | Evan Bauman, Erica Furfaro, Aram Green, Amanda Leithe, Margaret VitranoClearBridge Investments All Cap Growth | Life Sciences Tools & ServicesLife Sciences Tools & Services | ClearBridge Investments All Cap Growth 2025 Q2 (ICLR) Biotech funding challenges and government funding pressure have negatively impacted companies supporting biopharmaceutical development like contract research organization (CRO) ICON. This has pushed... | BULL | View Pitch → | |
| Dec 4, 2025 | Fund Letter | Kris Webster, Michael Poulsen, and Jack McManusCanopy Investors | Life Sciences Tools & ServicesLife Sciences Tools & Services | Canopy Investors 2025 Q2 (ICLR) Icon, a top-tier global clinical research organisation (CRO), saw a 25% reduction in consensus 2027 EPS estimates during the year, and a more than 50% decline in its stock price. In our view,... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | Michael P. McCloskeyGreensKeeper Value Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | GreensKeeper Value Fund 2025 Q3 (ICLR) ICON plc was the second top contributor in Q3, rising +20.3%. The fund initiated... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.